Table 2.
Age, eGFR slope and 1/Cr slope in relation to the CKD stages of initially measured eGFR
| CKD stages according to initially measured eGFRa (ml/min/1.73 m2) | P value | ||||
|---|---|---|---|---|---|
| Stage 1 ≥90 |
Stage 2 89–60 |
Stage 3 59–30 |
Stage 4 + 5b
≤29 |
||
| Initial eGFR (ml/min/1.73 m2) | 113.8 ± 25.9 | 75.1 ± 7.9 | 45.0 ± 8.8 | 16.3 ± 8.0 | – |
| Patient number | 32 | 62 | 71 | 31 | – |
| Age (years) | 29.9 ± 11.4 | 42.4 ± 10.2 | 52.4 ± 12.1 | 55.0 ± 8.4 | <0.0001 |
| eGFR slopec (ml/min/1.73 m2/year) | −4.2 ± 9.5 | −3.5 ± 4.1 | −3.1 ± 3.3 | −2.8 ± 1.7 | 0.6775 |
| eGFR slope/initial eGFR × 100 (%/year) | −3.2 ± 8.0 | −4.8 ± 5.4 | −7.5 ± 8.5 | −16.4 ± 10.3 | <0.0001 |
| 1/Cr sloped (dl/mg/year) | −0.04 ± 0.13 | −0.05 ± 0.07 | −0.06 ± 0.07 | −0.05 ± 0.03 | 0.8982 |
| 1/Cr slope/initial 1/Cr × 100 (%/year) | −2.2 ± 7.4 | −4.0 ± 5.1 | −6.7 ± 8.1 | −15.1 ± 9.6 | <0.0001 |
Data are presented as the mean ± SD. P values are calculated by ANOVA
aPatients were staged according to the National Kidney Foundation Disease Outcomes Quality Initiative guidelines
bESRD (dialysis and transplantation) is not included in stage 4 and 5 groups
ceGFR slope is the annual change of estimated GFR
d1/Cr slope is the annual change of 1/Cr